Abstract

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

Original languageEnglish
Pages (from-to)543-545
JournalMultiple Sclerosis
Volume24
Issue number4
Early online date1 Apr 2017
DOIs
Publication statusPublished - Apr 2018

Cite this